Tech Company Financing Transactions
Orca Bio Funding Round
Orca Bio secured a $250 million Series F financing round on 1/12/2026. Investors included Lightspeed Venture Partners and Silicon Valley Bank.
Transaction Overview
Company Name
Announced On
1/12/2026
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$250,000,000
Round
Series F
Investors
Lightspeed Venture Partners (Lead Investor)
Proceeds Purpose
The proceeds will be used to ensure commercial readiness as the company approaches the April 6, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Orca-T, Orca Bio's lead investigational allogeneic T-cell immunotherapy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3475 Edison Way C
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
Established in 2016, Orca Bio is a clinical-stage biotechnology company developing a pipeline of high-precision allogeneic cell therapy products. Our products are designed to safely and effectively replace a patient's diseased blood and immune system with a healthy one.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ivan Dimov
Chief Scientific Officer
Nathaniel Fernhoff
Chief Scientific Officer
James McClellan
VP - Engineering
Khiem Do
Browse more venture capital transactions:
Prev: 1/12/2026: Avenue Biosciences venture capital transaction
Next: 1/13/2026: Juvena Therapeutics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs